Skip to main content

Advertisement

SpringerLink
Log in

A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Introduction

The management of unresectable, chemorefractory colorectal cancer liver metastases (CRCLM) is a clinical dilemma. Yttrium-90 (Y90) radioembolization is a potentially safe and effective treatment for patients with CRCLM who have failed conventional chemotherapy regimens.

Methods

A systematic review of clinical studies before November 2012 was performed to examine the radiological response, overall survival and progression-free survival of patients who underwent Y90 radioembolization of unresectable CRCLM refractory to systemic therapy. The secondary objectives were to evaluate the safety profile of this treatment and identify prognostic factors for overall survival.

Results

Twenty studies comprising 979 patients were examined. Patients had failed a median of 3 lines of chemotherapy (range 2–5). After treatment, the average reported value of patients with complete radiological response, partial response and stable disease was 0 % (range 0–6 %), 31 % (range 0–73 %) and 40.5 % (range 17–76 %), respectively. The median time to intra-hepatic progression was 9 months (range 6–16). The median overall survival was 12 months (range 8.3–36). The overall acute toxicity rate ranged from 11 to 100 % (median 40.5 %). Most cases of acute toxicity were mild (Grade I or II) (median 39 %; range 7–100 %) which resolved without intervention. The number of previous lines of chemotherapy (≥3), poor radiological response to treatment, extra-hepatic disease and extensive liver disease (≥25 %) were the factors most commonly associated with poorer overall survival.

Conclusion

Y90 radioembolization is a safe and effective treatment of CRCLM in the salvage setting and should be more widely utilized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644–657 discussion 57–58

    Article  PubMed Central  PubMed  Google Scholar 

  • Albert M, Kiefer MV, Sun W et al (2011) Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117:343–352

    Article  CAS  PubMed  Google Scholar 

  • Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37

    Article  CAS  PubMed  Google Scholar 

  • Beppu T, Hayashi N, Masuda T et al (2010) FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res 30:1015–1020

    CAS  PubMed  Google Scholar 

  • Chua TC, Bester L, Saxena A, Morris DL (2011) Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 137:865–873

    Article  CAS  PubMed  Google Scholar 

  • Cianni R, Urigo C, Notarianni E et al (2009) Selective internal radiation therapy with SIRspheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol 32:1179–1186

    Article  PubMed  Google Scholar 

  • Colorectal Cancer Facts and Figures 2011–2013. American Cancer Society (2013). (Accessed Mar 3 2013, at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf)

  • Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Falcone A, Ricci S, Brunetti I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest. J Clin Oncol 25:1670–1676

    Article  CAS  PubMed  Google Scholar 

  • Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterial infusion of irinotecan-loaded drugeluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32:1387–1395

    CAS  PubMed  Google Scholar 

  • Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:38–47

    Article  CAS  PubMed  Google Scholar 

  • Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  CAS  PubMed  Google Scholar 

  • Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy versus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720

    Article  CAS  PubMed  Google Scholar 

  • Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312

    Article  CAS  PubMed  Google Scholar 

  • Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694

    Article  CAS  PubMed  Google Scholar 

  • Hong K, McBride JD, Georgiades CS et al (2009) Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 20:360–367

    Article  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Jakobs TF, Hoffmann RT, Dehm K et al (2008) Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 19:1187–1195

    Article  PubMed  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J med 359:1757–1765

    Article  CAS  PubMed  Google Scholar 

  • Kemeny N, Fata F (1999) Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg 6:39–49

    Article  CAS  PubMed  Google Scholar 

  • Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459–465

    Article  CAS  PubMed  Google Scholar 

  • Kemeny NE, Niedzwiecki D, Hollis DR et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403

    Article  CAS  PubMed  Google Scholar 

  • Kennedy AS, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425

    Article  CAS  PubMed  Google Scholar 

  • Khatri VP, Chee KG, Petrelli NJ (2007) Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 16:71–83

    Article  PubMed  Google Scholar 

  • Lewandowski RJ, Thurston KG, Goin JE et al (2005) 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16:1641–1651

    Article  PubMed  Google Scholar 

  • Lim L, Gibbs P, Yip D et al (2005) A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC cancer 5:132

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mancini R, Carpanese L, Sciuto R et al (2006) A multicentric phase II clinical trial on intraarterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo 20:711–714

    CAS  PubMed  Google Scholar 

  • Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18:192–198

    Article  PubMed  Google Scholar 

  • Martin LK, Cucci A, Wei L et al (2012) Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin colorectal cancer 11:195–199

    Article  PubMed  Google Scholar 

  • Melichar B (2012) Hepatic arterial infusion in colorectal carcinoma: is anatomical targeting still relevant in an era of molecularly targeted therapy? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156:81–92

    Article  PubMed  Google Scholar 

  • Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858

    Article  PubMed  Google Scholar 

  • Murthy R, Xiong H, Nunez R et al (2005) Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 16:937–945

    Article  PubMed  Google Scholar 

  • Murthy R, Eng C, Krishnan S et al (2007) Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol 18:1588–1591

    Article  PubMed  Google Scholar 

  • Nace GW, Steel JL, Amesur N et al (2011) Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol 2011:571261

    PubMed Central  PubMed  Google Scholar 

  • Nishiofuku H, Tanaka T, Matsuoka M et al (2013) Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study. J Vasc Interv Radiol 24:56–65

    Article  PubMed  Google Scholar 

  • Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Riemsma RP, Bala MM, Wolff R, Kleijnen J (2012) Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane database of systematic reviews 9: CD009498

  • Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. irinotecan study group. N Engl J med 343:905–914

    Article  CAS  PubMed  Google Scholar 

  • Seidensticker R, Denecke T, Kraus P et al (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 35:1066–1073

    Article  PubMed  Google Scholar 

  • Stuart JE, Tan B, Myerson RJ et al (2008) Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. J Vasc Interv Radiol 19:1427–1433

    Article  PubMed  Google Scholar 

  • Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696–703

    Article  PubMed  Google Scholar 

  • Tomlinson JS, Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580

    Article  PubMed  Google Scholar 

  • Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019

    Article  PubMed  Google Scholar 

  • van Hazel GA, Pavlakis N, Goldstein D et al (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:4089–4095

    Article  PubMed  Google Scholar 

  • Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M (2007) Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 17:1025–1034

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. UNSW Department of Surgery, St George Hospital, Kogarah, NSW, 2217, Australia

    Akshat Saxena, Leonard Shan, Marlon Perera & David L. Morris

  2. Department of Interventional Radiology, St Vincent’s Hospital Sydney, Darlinghurst, Sydney, NSW, 2010, Australia

    Lourens Bester & Baerbel Meteling

  3. Department of Medical Oncology, Royal Melbourne Hospital, Parkville, VIC, 3050, Australia

    Peter Gibbs

Authors
  1. Akshat Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lourens Bester
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonard Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marlon Perera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Gibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Baerbel Meteling
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David L. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akshat Saxena.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saxena, A., Bester, L., Shan, L. et al. A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. J Cancer Res Clin Oncol 140, 537–547 (2014). https://doi.org/10.1007/s00432-013-1564-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-013-1564-4

Keywords

Search

Navigation